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oRIGINAL ARTICLE
Introduction: The specific aims of the study were to evaluate the 
2-year overall survival (oS) and progression-free survival (PFS), 
toxicity profile, and best objective response rate in patients with 
locally advanced, clinically unresectable esophageal cancer receiv-
ing cetuximab, cisplatin, irinotecan, and thoracic radiotherapy (TRT) 
within a multi-institutional cooperative-group setting.
Methods: Eligible patients (cT4 M0 or medically unresectable, 
biopsy proven, and noncervical esophageal cancer) were to receive 
four 21-day cycles of cetuximab 400 mg/m2 (day 1, cycle 1), cetux-
imab 250 mg/m2 (day 8, 15, cycle 1; then days 1, 8, and 15 for sub-
sequent cycles), cisplatin 30 mg/m2 (days 1 and 8, all cycles), and 
irinotecan 65 mg/m2 (days 1 and 8, all cycles). TRT was administered 
at 1.8 Gy in 28 daily fractions to a total dose of 50.4 Gy, to begin with 
on day 1 of cycle 3. The primary endpoint was 2-year oS, with an 
accrual goal of 75 patients with adenocarcinoma.
Results: The study was closed because of slow accrual, with 21 eli-
gible patients (11 squamous, 10 adenocarcinoma) enrolled from May 
2005 to September 2007. Two-year oS and PFS (95% confidence 
interval [CI]) were 33.3% (14.6–57.0%) and 23.8% (8.2–47.2%), 
respectively. Kaplan–Meier estimates of median (95% CI) oS and 
PFS were 11.2 (6.4–43.6) and 6.4 (3.7–12.0) months, respectively. 
The overall response rate (95% CI) among 17 evaluable patients was 
17.6% (3.8–43.4%), including 6% confirmed complete responders 
and 12% unconfirmed partial responders. Two deaths resulted from 
protocol treatment (sudden death and gastrointestinal necrosis). Ten 
(47.6%) and 6 (28.6%) patients had grade-3 or -4 toxicity, respec-
tively: 52.4% were hematologic, 23.8% had fatigue, 19.0% had nau-
sea, 19.0% had dehydration, and 19.0% had anorexia.
Conclusions: Concomitant cetuximab, cisplatin, irinotecan, and TRT 
were poorly tolerated in the first North American cooperative group 
trial testing this regimen for locally advanced esophageal cancer as 
treatment-related mortality approached 10%. Single-institution phase-II 
cetuximab-based combined modality trials have yielded encouraging 
results in preliminary analyses. The SWoG GI Committee endorses 
enrollment to open clinical trials to clarify the therapeutic ratio of cetux-
imab-based combined modality approaches for esophageal cancer.
Key Words: Esophageal, Cetuximab, Cisplatin, Irinotecan, 
Radiotherapy.
(J Thorac Oncol. 2012;7: 906–912)
An estimated 17,460 new cases of esophageal cancer will be diagnosed in the United States in 2012, accompanied 
by 15,070 deaths from the disease.1 It is the fifth leading cause 
of cancer deaths in men over the age of 40 years. The National 
Comprehensive Cancer Network guidelines recommend the con-
comitant administration of cisplatin, 5-fluorouracil (5-FU), and 
thoracic radiotherapy (TRT) as definitive therapy for patients 
with locally advanced esophageal cancer. Both cisplatin and 
5-FU have proven to be relatively effective radiosensitizing 
agents in preclinical and clinical experience over the past two 
decades. Radiation Therapy oncology Group (RToG) 85-01 
demonstrated a 27% 5-year survival compared to 0% for patients 
receiving the combined-modality regimen over TRT (6400 cGy) 
alone.2,3 Despite the addition of systemic cytotoxic agents to 
TRT, local failure within the gross tumor volume (GTV) remains 
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the most common cause of treatment failure.4 A Patterns of Care 
analysis by the American College of Radiology for the period 
of 1996–1999 suggests that 56% of patients with esophageal 
cancer receive combined-modality therapy as definitive therapy.5 
Infusional 5-FU delivered over several days can be cumbersome 
and the toxicity profile may be so profound as to preclude an 
adequate number of courses, despite its efficacy. Thus, there is a 
pressing need for effective, less toxic, and novel treatment pro-
grams for patients with locally advanced esophageal cancer.6
Irinotecan, a topoisomerase-I enzyme inhibitor, is a semi-
synthetic, water-soluble derivative of the plant Camtotheca 
acuminata and inhibits topo-1, a nuclear enzyme, via binding 
and stabilization of the topo-1/DNA cleavable complex.7 A 
22% objective response rate in advanced esophageal and gas-
tric cancer has been reported, using irinotecan combined with 
a 5-FU/folinic acid backbone.8 This study and other irinotecan-
based studies (408 total combined patients) on esophageal and 
gastric cancer suggest response rates of 14% to 65%.7,9–15
In vitro and in vivo data suggest that irinotecan exhibits 
significant radiosensitizing properties.16–20 Phase-I experience 
with single-agent irinotecan and TRT noted that 60 mg/m2 
weekly for 5 to 6 weeks could be safely administered in a com-
bined-modality setting.21 on the basis of published phase-II 
experience of weekly irinotecan and cisplatin for advanced 
esophageal cancer that demonstrated a 57% overall response 
rate (including two clinical complete responses) along with a 
nearly 15-month median actuarial survival, investigators added 
TRT to this regimen for patients with stage-II or -III lesions.12 
A dose-escalation study of weekly irinotecan, fixed-dose cis-
platin, and TRT after 4 weeks of induction therapy (irinotecan 
65 mg/m2 weekly and cisplatin 30 mg/m2 weekly), determined 
that the maximum tolerated dose of irinotecan was 65 mg/m2 
weekly for 5 weeks.22 TRT was administered at 5040 cGy in 
standard 180 cGy fractions. This combination of non-5-FU-
based chemoradiotherapy was shown to be safe and therapeu-
tically active against primary esophageal cancer. Moreover, 
the pathologic complete response rate of 32% was consistent 
with prior results in the literature that included infusional fluo-
rinated pyrimidine-based chemoradiotherapy. The same group 
recently reported the results of a phase-II study of induction 
weekly irinotecan and cisplatin followed by the same regimen 
concurrent with TRT to 5040 cGy, followed by surgery.23 R0 
resection was obtained in 69% of the patients, and the patho-
logic complete response rate was 16%. Postinduction positron 
emission tomography response was correlated with better clin-
ical outcomes. A retrospective analysis of induction cisplatin 
and irinotecan followed by concurrent cisplatin, irinotecan, 
and TRT with a median follow-up of 2 years reported a 2-year 
oS of 42% and acceptable tolerability of this regimen.24
Cetuximab is a novel chimeric monoclonal antibody 
directed against the external domain of the epidermal growth 
factor receptor (EGFR). This agent is able to inhibit the activity 
of tyrosine kinase on the inner surface of the cell membrane. 
This results in inhibition of downstream events within the sig-
nal transduction cascade from the cell surface to the nucleus. 
Preclinical data suggest that cetuximab has radiosensitizing 
properties.25 Its utility combined with radiotherapy has been 
demonstrated for squamous-cell carcinoma of the head and 
neck.26 Cetuximab has been safely used in combination with 
cisplatin27,28 and with irinotecan,29,30 and evidence suggests 
that cetuximab acts to enhance irinotecan’s cytotoxic proper-
ties by down-regulating EGFR pathways the topoisomerase 
inhibitor is known to up-regulate.31
Consequently, a novel form of antitumor activity may 
occur to support this study’s hypotheses that:
1. As definitive therapy for primary locally advanced and 
clinically unresectable esophageal cancer, cetuximab, in 
combination with cisplatin, irinotecan, and TRT will pro-
duce a favorable response rate and survival.
2. In combination with cisplatin, irinotecan, and TRT, 
cetuximab will cause significantly less clinical toxicity 
than 5-FU-based chemoradiotherapy, a current standard 
of care for patients receiving either neoadjuvant or defin-
itive combined-modality therapy for esophageal cancer. 
Cisplatin and irinotecan can be administered in full doses 
when given with cetuximab.
3. Patients with primary esophageal tumors expressing low 
levels of ERCC-1 and high levels of EGFR will exhibit an 
encouraging progression-free survival (PFS) and clinical 
complete response rate after definitive treatment with cetux-
imab, cisplatin, irinotecan, and external beam radiation.
PATIENTS AND METHODS
Patients with pathologically documented squamous-cell 
carcinoma or adenocarcinoma of the thoracic esophagus (≥20 
cm from the incisors) or of gastroesophageal junction were con-
sidered eligible, and all had measurable or evaluable cT4 M0 
or unresectable disease. History, physical examination, endo-
scopic ultrasound or esophagogastroduodenoscopy, chest radi-
ography, positron emission tomography scans with computed 
tomography or magnetic resonance imaging, and adequate renal 
and hepatic function, absence of prior cancer, absence of prior 
chemotherapy or radiotherapy, Zubrod performance status 0 to 
2, and Institutional Review Board-approved informed consent 
were all required. A baseline electrocardiogram and pulmonary-
function studies were recommended. Bronchoscopy with nega-
tive cytology was required for patients with a primary tumor less 
than 26 cm from the incisors. Patients with clinical evidence of 
tracheo-esophageal fistulas were ineligible for this trial.
Induction Chemotherapy
Two cycles of cetuximab 400 mg/m2 intravenous (IV) 
loading dose on day 1 followed by 250 mg/m2 (days 18, 15; 
and days 22, 29, and 36), cisplatin 30 mg/m2 IV bolus (days 
1, 8; and days 22, 29), and irinotecan 65 mg/m2 (days 1, 8; 
and days 22, 29) combination chemotherapy were adminis-
tered. Cisplatin was administered after adequate hydration. 
Cetuximab was provided courtesy of ImClone, a wholly owned 
subsidiary of Eli Lilly and Co. (Indianapolis, IN), and Bristol-
Myers-Squibb (New York, NY). Standard pretreatment agents 
were administered.
Concurrent Chemotherapy
Following the completion of induction chemotherapy, con-
current chemoradiotherapy was initiated with the first fraction 
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of TRT. Concurrent systemic therapy consisted of two cycles of 
cetuximab 250 mg/m2 IV (days 43, 50, and 57; 64, 71, and 78), 
cisplatin 30 mg/m2 IV (days 43, 50; and 64, 71), and irinotecan 
65 mg/m2 IV (days 43, 50; and 64, 71).
Radiotherapy
Three-dimensional-conformal megavoltage radiother-
apy (IMRT was not allowed) was administered at 1.8 Gy in 
28 daily fractions (excluding weekends and holidays) to a 
total dose of 50.4 Gy, timed to begin concurrently with che-
motherapy. The GTV included the primary tumor mass and 
involved lymph nodes. This GTV included the celiac nodal 
region in patients with tumor in the distal third of the esopha-
gus. A clinical target volume (CTV) was derived by expand-
ing the GTV 5 cm superiorly and inferiorly for the primary 
tumor, and at least 2 cm around any involved lymph nodes. For 
patients with tumor extending at least 2 cm above the carina, 
the CTV included the supraclavicular nodal regions. Margins 
for expansion to the planning target volume were left to the 
discretion of the treating radiation oncologist. Heterogeneity 
corrections were applied, and at least 95% of the CTV received 
the prescribed dose. All TRT plans were centrally reviewed 
by the Quality Assurance Review Center (Providence, RI) for 
compliance with the study parameters.
Growth Factor S upport
The use of granulocyte-colony stimulating factor was 
permitted only for patients who developed grade 3 or 4 neu-
tropenia. Granulocyte-colony stimulating factor was not per-
mitted for primary prevention of neutropenia.
Dose Modifications
No dose modifications for radiotherapy were allowed. 
A hemogram was performed before systemic therapy on each 
infusion day. Irinotecan was to be held for white blood count 
less than 3000/ul, absolute neutrophil count less than 1000/ul, 
or platelets <less than 100,000/ul; for febrile neutropenia or 
bleeding complications; for grade-2+ mucositis or diarrhea; 
or for grade-4 fatigue lasting more than 3 days. Cisplatin 
was dose reduced for a moderate increase in creatinine but 
was omitted for creatinine more than 2.0 mg/dl, permanently 
discontinued for grade-3+ peripheral neuropathy, and dose 
reduced by 25% for other grade-3+ nonhematologic toxicity. 
Cetuximab was discontinued for grade-4 acneiform rash; it 
was delayed and its dose was potentially reduced for grade-3 
rash, but no dose modifications were made for grade-1 or -2 
rash. Grade-1 or -2 infusion reaction from cetuximab was an 
indication for a permanent 50% dose reduction; Grade-3 or 
-4 infusion reactions led to permanent discontinuation of the 
drug. All patients were prophylactically treated with oral tet-
racycline and topical clindamycin.
Assessment of Response
The objective response was evaluated according to the 
response evaluation criteria in solid tumors criteria. All toxici-
ties were scored according to the CTCAE, version 3.0 (NCI 
Common Terminology Criteria for Adverse Events).
Statistical Methods
The main objective of the study was to assess the 2-year 
overall survival (oS) of this novel therapeutic combination. 
This primary endpoint was driven by accrual of patients with 
adenocarcinoma, although up to 25 patients with squamous-
cell tumors were eligible for enrollment. The regimen was to 
be considered promising if the true oS at 2 years was at least 
50%, but not of further interest if the true survival rate was 
less than 35%. With a planned 75 adenocarcinoma patients, 
the power of a one-sided 0.05 level test to detect a 35% ver-
sus a 50% 2-year oS was 0.91. Additional endpoints included 
assessment of the toxicity profile of this regimen, best objec-
tive response to therapy, and PFS.
RESULTS
The study was closed because of slow accrual, with 
only 22 patients enrolled from May 2005 to September 2007. 
one patient was ineligible because of involvement of the cer-
vical esophagus. The baseline characteristics of the 21 eli-
gible patients are described in Table 1. The median age was 
61 years (range, 43–83 years).
Toxicities
Toxicity data for the 21 eligible patients are presented 
in Table 2. Eighteen patients (85.7%) exhibited a maximum 
grade-3 or higher toxicity. of the eight patients (38.1%) expe-
riencing grade-4 or higher toxicity, five had squamous-cell 
and three had adenocarcinoma histology. Treatment-related 
mortality was observed in two patients (9.5%, sudden death 
and gastrointestinal necrosis), both of whom has squamous-
cell histology. In both cases, the treating physician felt that 
protocol treatment may have been a contributing factor. The 
most common grade-3 or higher toxicities were leukopenia 
(42.9%), neutropenia (28.6%), fatigue (23.8%), lymphope-
nia (19.0%), dehydration (19.0%), and gastrointestinal com-
plaints (diarrhea [23.8%], nausea [19.0%], and anorexia 
[19.0%]). Febrile neutropenia was seen in fewer than 5% of 
the patients. Eighteen patients (85.7%) were able to complete 
treatment as planned (two deaths, one stopped because of 
side effects).
TABLE 1. Baseline patient characteristics/demographics  
(N = 21)
Age
 Median 61.4 (43–83)
Sex
 Male 15 (71%)
 Female 6 (29%)
Race
 Caucasian 15 (71%)
 African-American 4 (19%)
 Asian 2 (10%)
Histology
 Adenocarcinoma 10 (48%)
 Squamous cell 11 (52%)
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6.4–43.6 months). The median (95% CI) PFS was 6.4 months 
(range, 3.7–12.0 months). Two-year oS and PFS is 33.3% 
(95% CI: 14.6–57.0%) and 23.8% (95% CI: 8.2–47.2%), 
respectively. Two-year oS (95% CI) within the 11 patients 
with squamous-cell histology and the 10 patients with adeno-
carcinoma is 45.5% (16.0–74.9%) and 20.0% (0.0–44.8%), 
respectively. Kaplan–Meier curves for overall and PFS for 
the entire study population are shown in Figures 1 and 2, 
respectively.
DISCUSSION
The long-term results of RToG 85-01 suggest that one 
of four good-performance patients with locally advanced 
esophageal cancer, who are able to successfully receive con-
comitant chemoradiotherapy will be alive at the 5-year mark.3 
Patients with clinically T4 primary esophageal cancers often 
have suboptimal performance status, in part, because of the 
symptoms consistent with the invasion of adjacent structures,32 
although preoperative combined modality approaches have 
been reported with variable success.33,34
Building on the platform of RToG 85-01, investiga-
tors have attempted to both increase the intensity of treat-
ment by adding surgery (trimodality) often after preoperative 
combined modality therapy, and by adding full-dose sys-
temic therapy. Strategic induction approaches allow both 
the opportunity of administering full-dose systemic ther-
apy and serving as an in-vivo assessment of response with 
novel systemic therapeutics before the administration of a 
Response
objective responses were assessed by the investigators 
at the treating institution using response evaluation criteria in 
solid tumors criteria; 17 were evaluable. The overall response 
rate was 17.6% (95% confidence interval [CI]: 3.8–43.4%), 
including one complete response (5.9%) and two unconfirmed 
partial responses (11.8%). All responders had squamous-cell 
histology. Three patients (17.6%) exhibited stable disease, 
four (23.5%) had progressive disease, and six (35.3%) with 
inadequate assessment were considered nonresponders. These 
results are summarized in Table 3.
Survival
With over 3.5 years of follow-up among those last 


















FIGURE 1. Kaplan-Meier curve of overall survival (OS) in 
SWOG S0414.
TABLE 3. Best Objective Response by Response Evaluation 
Criteria in Solid Tumors Criteria (N = 17 Measurable)
Total
Complete response 1 6%
Unconfirmed partial response 2 12%
Stable/No response 3 18%
Progressive disease 4 24%
Symptomatic deterioration 1 6%
Assessment inadequate 6 35%
Total 17 100%
TABLE 2. Maximum Grade of Adverse Events by Category 
(Maximum Grade Experienced by Patient for Each Category) 
(N = 21)
Grade 3 (%) 4 (%) 5 (%)
Hematologic
 Anemia 14.3 — —
 Leukopenia 33.3 9.5 —
 Lymphopenia 9.5 9.5 —
 Neutropenia 14.3 14.3 —
 Neutropenia, febrile 4.8 — —
Nonhematologic
 Acneiform rash 4.8 — —
 Anorexia 19.0 — —
 CNS ischemia — 4.8 —
 Creatinine — 4.8 —
 Dehydration 19.0 — —
 Diarrhea 23.8 — —
 Dysphagia 14.3 — —
 Esophagitis 9.5 — —
 Fatigue 23.8 — —
 GI necrosis — — 4.8
 GI pain: abdomen 4.8 — —
 GI pain: esophagus 4.8 — —
 GI perforation: colon 4.8 — —
 Hyperglycemia 4.8 — —
 Hypoalbuminemia 4.8 — —
 Hypocalcemia 4.8 — —
 Hypokalemia 9.5 — —
 Hypomagnesemia 4.8 — —
 Hyponatremia 4.8 — —
 Nausea 19.0 — —
 Neuropathy 4.8 — —
 Renal failure — 4.8 —
 Skin lesions 4.8 — —
 Sudden death — — 4.8
 Thrombosis/embolism — 4.8 —
 Typhlitis — 4.8 —
 Vomiting 14.3 — —
 Weight loss 4.8 — —
CNS, central nervous system; GI, gastrointestinal.
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concomitant chemoradiotherapy platform. Several investiga-
tors have successfully tested induction systemic combination 
chemotherapy and/or molecular targeted therapeutics, before 
concomitant chemotherapy.35
one of the combination cytotoxic chemotherapy regi-
mens upon which the present study was based included irino-
tecan and cisplatin. This doublet yielded encouraging objective 
responses, including some clinical complete responses, in 
patients with unresectable or metastatic esophageal can-
cer.12,13 Furthermore, a phase-1 trial of weekly irinotecan and 
cisplatin plus concomitant TRT by an experienced group of 
investigators noted an acceptable toxicity profile along with 
encouraging observations of symptomatic improvement and 
objective responses.21 A phase-II trial by the MD Anderson 
Cancer Center group modified this regimen by first adminis-
tering induction irinotecan and cisplatin for one or two cycles 
followed by chemoradiotherapy using a 5-FU, paclitaxel, TRT 
backbone before surgery for patients with clinically resect-
able disease.36 More recently, the Spanish Cooperative Group 
for Digestive Tumor Therapy’s phase II trial that included 
induction irinotecan and cisplatin followed by concomitant 
chemoradiotherapy with the same two drugs before surgical 
resection, noted acceptable toxicity and modest activity com-
pared to the historical published experience of cisplatin, 5-FU, 
and TRT in patients with clinically resectable disease.37 When 
this study group and others tested this regimen in patients 
with clinically unresectable disease, the results were even less 
favorable.22,38
over the past decade, there has been significant progress 
in characterizing mechanisms of tumor growth that result from 
altered regulation of various parts of the signal-transduction 
pathway. At the turn of the century the EGFR, a member of the 
ErbB family of growth-factor receptor tyrosine kinases, was 
reported to be overexpressed in a number of epithelial tumors 
of the upper aerodigestive tract, including esophageal cancer, 
hence suggesting a target that could be used to make progress 
with this difficult-to-treat solid tumor.39,40 Midway during the 
decade the concomitant administration of the chimeric mono-
clonal antibody against the EGFR, cetuximab, and ionizing 
radiation was shown to yield a superior survival outcome in 
patients with head and neck cancer.23,24
on the basis of encouraging preclinical and clinical data 
cetuximab and ionizing radiation, and the phase-I/II results of 
irinotecan–cisplatin and TRT in 2004 SWoG, a federally funded 
cancer research group, designed a phase-II clinical trial for 
esophageal-cancer patients. SWoG-0414 is the first U.S. multi-
institutional, prospective, cooperative-group trial incorporating 
the novel combination of cetuximab, cisplatin, and irinotecan 
in patients with locally advanced or unresectable esophageal 
cancer. This regimen was poorly tolerated, with 38% of patients 
experiencing grade-4 or -5 toxicities and a treatment-related 
mortality approaching 10%. The objective response rate was 
disappointing, with only one CR and two unconfirmed PRs to 
therapy, all among patients with squamous-cell histology.
No patients in this study experienced grade-3 or higher 
pulmonary toxicity. This is in contrast to the recently reported 
results of Eastern Cooperative oncology Group 2205, a phase-
II study examining the addition of cetuximab to concurrent 
oxaliplatin, 5-FU, and 45 Gy TRT delivered as neoadjuvant 
therapy before surgery for patients with resectable adenocar-
cinoma of the esophagus.41 Despite a promising pathologic CR 
rate, four out of 22 patients died from ARDS postoperatively, 
compared to no incidence of ARDS in ECoG 1201 without 
cetuximab. other reports of concurrent chemoradiation for 
esophageal cancer using cetuximab have not shown signifi-
cant pulmonary toxicity.42,43
This trial was closed because of slow accrual. A poten-
tial confounding factor is that SWoG sites were concurrently 
accruing to SWoG-0356, a protocol for resectable esophageal 
adenocarcinoma. Patients with technically resectable cT4 
disease may have preferentially been enrolled on SWoG-
0356, skewing the population to the medically unresectable 
patients for this trial. This could also explain the poor accrual 
for adenocarcinomas and the fact that the majority of patients 
enrolled on this trial had squamous tumors. Furthermore, we 
may have chosen a suboptimal doublet to combined with TRT, 
as others have reported superior tolerability with a carbopl-
atin–paclitaxel backbone during concomitant therapy.33,39,44 
In addition, investigators have recently shown that the actual 
expression of EGFR may range from low to nonexistent for 
esophageal adenocarcinomas.45
Given the unfavorable results of this trial, we would 
not recommend further development of this particular regi-
men for patients with locally advanced or medically unresec-
table esophageal cancer. Several other studies in esophageal 
and non–small-cell lung cancer have shown safe and effective 
combination of cetuximab and radiotherapy, and we believe 
that alternative cetuximab-based chemoradiotherapy regi-
mens may hold promise for esophageal cancer.39,40,46 Although 
recent reports of combining chemoradiotherapy with oral 
tyrosine kinase inhibitors against EGFR, such as erlotinib, 
demonstrate feasibility, we believe that significant dysphagia 
will likely result in noncompliance in a prospective, multi-
institutional trial for patients with advanced esophageal can-
cer.47,48 The RToG is currently conducting a phase-III trial 
examining the addition of cetuximab to paclitaxel, cisplatin, 
and TRT for unresectable esophageal cancer, and we would 
encourage enrollment to this pivotal trial. In addition to this,, 


















FIGURE 2. Kaplan-Meier curve of progression-free survival 
(PFS) in SWOG S0414.
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to accrual.49 This multicenter phase-II/III study randomizes 
patients with locally advanced esophageal cancer to induction 
cisplatin and capecitabine followed by the same regimen con-
current with TRT (5000 cGy in 200 cGy fractions) versus the 
investigational arm that simply adds cetuximab to the induction 
and concurrent chemotherapy of the control arm. The results of 
these two randomized trials will help to answer the question of 
the role of cetuximab in this patient population.
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